MX2024013240A - Tratamiento de trastornos neurologicos - Google Patents

Tratamiento de trastornos neurologicos

Info

Publication number
MX2024013240A
MX2024013240A MX2024013240A MX2024013240A MX2024013240A MX 2024013240 A MX2024013240 A MX 2024013240A MX 2024013240 A MX2024013240 A MX 2024013240A MX 2024013240 A MX2024013240 A MX 2024013240A MX 2024013240 A MX2024013240 A MX 2024013240A
Authority
MX
Mexico
Prior art keywords
disorder
treatment
neurological disorders
function
disorder associated
Prior art date
Application number
MX2024013240A
Other languages
English (en)
Spanish (es)
Inventor
Michael Kristopher Mathieu Kahlig
Marion Wittmann
Zoe A Hughes
Bernard Ravina
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2024013240A publication Critical patent/MX2024013240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024013240A 2022-04-26 2023-04-24 Tratamiento de trastornos neurologicos MX2024013240A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263335204P 2022-04-26 2022-04-26
US202263349402P 2022-06-06 2022-06-06
US202263357944P 2022-07-01 2022-07-01
PCT/US2023/019652 WO2023211852A1 (en) 2022-04-26 2023-04-24 Treatment of neurological disorders

Publications (1)

Publication Number Publication Date
MX2024013240A true MX2024013240A (es) 2024-12-06

Family

ID=88519529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013240A MX2024013240A (es) 2022-04-26 2023-04-24 Tratamiento de trastornos neurologicos

Country Status (12)

Country Link
US (2) US20250312338A1 (enExample)
EP (1) EP4514347A4 (enExample)
JP (1) JP2025515501A (enExample)
KR (1) KR20250005348A (enExample)
CN (1) CN119522099A (enExample)
AU (1) AU2023260468A1 (enExample)
CA (1) CA3250706A1 (enExample)
CL (1) CL2024003261A1 (enExample)
CO (1) CO2024015551A2 (enExample)
IL (1) IL316541A (enExample)
MX (1) MX2024013240A (enExample)
WO (1) WO2023211852A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114980899A (zh) * 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
PE20221280A1 (es) * 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
WO2025259553A1 (en) * 2024-06-09 2025-12-18 Praxis Precision Medicines, Inc. Methods of treatment of neurological disorders
CN121550436A (zh) * 2026-01-23 2026-02-24 四川大学华西医院 新靶点在结节性硬化症相关癫痫中的应用、组合物及联合用药方式

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1080712A (en) 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4112095A (en) 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
KR100669497B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100858357B1 (ko) 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CA2713521A1 (en) 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
MX342128B (es) 2008-12-24 2016-09-14 Bial - Portela & C A S A Compuestos farmaceuticos.
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
ES2642586T3 (es) * 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012151136A1 (en) 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2013045519A1 (en) 2011-09-27 2013-04-04 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
WO2014179492A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP2818471A1 (en) 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
DK3035926T3 (da) 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
NZ720651A (en) 2013-12-19 2017-12-22 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
ES2912073T3 (es) 2014-06-20 2022-05-24 Mitsubishi Chem Corp Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2015279377B2 (en) 2014-06-26 2019-09-12 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
WO2018098500A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
EA201991306A1 (ru) 2017-08-30 2020-03-20 Праксис Пресижн Медсинз, Инк. Соединения и способы их применения
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) * 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
CN114980899A (zh) 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Also Published As

Publication number Publication date
US12582652B2 (en) 2026-03-24
EP4514347A1 (en) 2025-03-05
WO2023211852A1 (en) 2023-11-02
CO2024015551A2 (es) 2024-11-28
US20250312338A1 (en) 2025-10-09
AU2023260468A1 (en) 2024-11-28
CL2024003261A1 (es) 2025-05-16
KR20250005348A (ko) 2025-01-09
IL316541A (en) 2024-12-01
CA3250706A1 (en) 2023-11-02
EP4514347A4 (en) 2026-04-22
CN119522099A (zh) 2025-02-25
US20250049790A1 (en) 2025-02-13
JP2025515501A (ja) 2025-05-15

Similar Documents

Publication Publication Date Title
MX2024013240A (es) Tratamiento de trastornos neurologicos
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
RU2680247C2 (ru) Средство, усиливающее эффект реабилитации после нервного повреждения, которое содержит производное простого алкилового эфира или его соль
CA2400916A1 (en) Aminoadamantane derivatives as therapeutic agents
CA2642465A1 (en) Novel pyrone-indole derivatives and process for their preparation
RU2010107284A (ru) Производные нафтиридина в качестве модуляторов калиевых каналов
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
MX2024013172A (es) Tratamiento de trastornos neurologicos
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
US20100016440A1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
NO962538L (no) 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister
MX2022011518A (es) Metodos para tratar deambulacion asociada a proteinopatia.
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
MA60154B1 (fr) Inhibiteurs de line-1 pour traiter une maladie
CR20200613A (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
NO960974L (no) Farmasöytisk preparat for behandling av synsnerveforstyrrelse med prostansyreforbindelser
CA2510514C (en) Alpha-aminoamide derivatives useful as antimigraine agents
SAITO et al. Effects of Bifemelane Hydrochloride (MCl-2016) on Acetylcholine Level Reduced by Scopolamine, Hypoxia and Ischemia in the Rats and Mongolian Gerbils
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
AU2013271841B2 (en) Method of prevention of neurological diseases
MX2024008691A (es) Composiciones y metodos de triptamina.